FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfilebioAffinity Technologies, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIAFW
bioAffinity Technologies, Inc. Stock AnalysisComprehensive stock analysis for bioAffinity Technologies, Inc. (BIAFW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBIAFW
BIAFW
bioAffinity Technologies, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BIAFW
  1. Home
  2. Stocks
  3. bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc.

🇺🇸BIAFW•NASDAQ

bioAffinity Technologies, Inc.

🇺🇸BIAFW•NASDAQ
Market cap
$5.52M

Your view on BIAFW

Mkt Cap
$5.52M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About bioAffinity Technologies, Inc.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Maria Zannes
Headquarters
3300 Nacogdoches Road, San Antonio, TX, US
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Maria Zannes
Headquarters
3300 Nacogdoches Road, San Antonio, TX, US
Description

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services.

The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for bioAffinity Technologies, Inc.. Starting points for bioAffinity Technologies, Inc.: EPS -$17.19, beta -1.05 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for bioAffinity Technologies, Inc.. Trailing twelve-month EPS for bioAffinity Technologies, Inc. stands at -$17.19. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026This yearYear to Dec 2026
Average estimate−$27.00−$121.50
Lowest estimate−$27.00−$121.50
Highest estimate−$27.00−$121.50
Number of analysts11
A year ago$5.981−$129.901
Growth vs a year ago——

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026This yearYear to Dec 2026
Average estimate$2.22M$7.31M
Lowest estimate$2.22M$7.31M
Highest estimate$2.22M$7.31M
Number of analysts11
A year ago$1.59M$6.16M
Growth vs a year ago+39.3%+18.6%

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for bioAffinity Technologies, Inc.. bioAffinity Technologies, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BIAFW19 companies
Compare BIAFW with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
BTAIBioXcel Therapeutics, Inc.HealthcareBiotechnology$2.3M
CCELCryo-Cell International, Inc.HealthcareMedical - Care Facilities$33.5M
ECORelectroCore, Inc.HealthcareMedical - Devices$40.8M
NMTCNeuroOne Medical Technologies CorporationHealthcareMedical - Devices$5.9M
PRPOPrecipio, Inc.HealthcareMedical - Diagnostics & Research$31.1M
RMTIRockwell Medical, Inc.HealthcareDrug Manufacturers - Specialty & Generic$23.5M
STRRStar Equity Holdings, Inc.IndustrialsConglomerates$30.7M
More Medical - Diagnostics & Research companies
TickerTypeCompanySectorExchangeMkt cap
SHL.AXSonic Healthcare LimitedHealthcareASX—
SKHCFSonic Healthcare LimitedHealthcareOTC$7.9B
AAgilent Technologies, Inc.HealthcareNYSE$48.0B
ABDXFAbingdon Health PlcHealthcareOTC$13.3M
ACL.AXAustralian Clinical Labs LimitedHealthcareASX—
ADVBAdvanced Biomed Inc. Common StockHealthcareNASDAQ$2.7M
ANPCFCellbxhealth PLCHealthcareOTC$4.5M
ARYCArrayit CorporationHealthcareOTC$79,348
AVCR.VAvricore Health Inc.HealthcareTSXV$3.2M
AVCRFAvricore Health Inc.HealthcareOTC$6.2M
BDSXBiodesix, Inc.HealthcareNASDAQ$61.5M
BDX.AXBCAL Diagnostics LimitedHealthcareASX—
Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by bioAffinity Technologies, Inc. executives and directors. Shares of bioAffinity Technologies, Inc. have traded between $0.06 and $0.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for bioAffinity Technologies, Inc.. Coverage tracks bioAffinity Technologies, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of bioAffinity Technologies, Inc.

BIAFW AnalysisFair
Past
1
Growth
5
Health
4
Profit
1
Value
1